Baird raised the firm’s price target on Neurocrine to $180 from $157 and keeps an Outperform rating on the shares. The firm said they posted a pretty astounding beat for a product now on the market 7+ years should shift the commercial curve up as demand remains surprisingly robust and there just doesn’t seem to be a shortage of new patients.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
- NBIX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Neurocrine launches Ingrezza capsules for dysphagia
- Neurocrine price target raised to $170 from $160 at Morgan Stanley
- Neurocrine price target raised to $173 from $169 at JPMorgan